Slavkovsky Rose C, Bansil Pooja, Sandoval Manuel A, Figueroa Jacqueline, Rodriguez Doris M, Lobo Jose Saul, Jeronimo Jose A, de Sanjosé Silvia
PATH, Seattle, WA.
Asociación Hondureña de Planificación de Familia (ASHONPLAFA), Tegucigalpa, Honduras.
JCO Glob Oncol. 2020 Oct;6:1565-1573. doi: 10.1200/GO.20.00400.
This study aims to assess the detection of cervical intraepithelial lesions grades 2 and 3 (CIN2-3) at 1 year after treatment with thermal ablation among human papillomavirus (HPV)-positive and visual inspection with acetic acid (VIA)-positive women.
All women screened and triaged for cervical cancer at four government health facilities in Honduras who were eligible for ablative treatment were enrolled and treated with thermal ablation. Women with confirmed CIN2-3 and a subset of women with CIN1/normal diagnoses at baseline were evaluated at 12 months. Follow-up procedures included HPV testing (HPV), VIA, directed biopsy (if VIA-positive), and Papanicolaou test (if HPV positive, VIA negative). Outcomes at 1 year included histologic or cytologic assessment of CIN lesions among those with any abnormal test.
Among the 319 women treated with thermal ablation, baseline histologic diagnoses were available for 317. Two (0.6%) had invasive cancer, 36 (11.4%) had CIN3, 40 (12.6%) had CIN2, and 239 (75.4%) had CIN1/normal histology. Among the 127 women eligible for follow-up, 118 (92.9%) completed all study procedures at 1 year. Overall, 98 (83.1%) had no evidence of CIN2-3 or persistent low-grade infection, 13 (11.2%) had CIN1/atypical squamous cells of undetermined significance, six (5.1%) had CIN2/high-grade squamous intraepithelial lesion, and 1 (0.8%) had a persistent CIN3. No adverse events associated with thermal ablation at 1 year were registered.
A high proportion of women had no evidence of CIN2-3 at 1 year after thermal ablation treatment. Thermal ablation is an alternative to cryotherapy that may facilitate greater treatment coverage and prevent unnecessary deaths from cervical cancer.
本研究旨在评估人乳头瘤病毒(HPV)阳性且醋酸肉眼观察(VIA)阳性的女性在接受热消融治疗1年后宫颈上皮内瘤变2级和3级(CIN2-3)的检出情况。
在洪都拉斯的四个政府卫生机构接受宫颈癌筛查和分流且符合消融治疗条件的所有女性均被纳入并接受热消融治疗。对确诊为CIN2-3的女性以及基线时诊断为CIN1/正常的部分女性在12个月时进行评估。随访程序包括HPV检测(HPV)、VIA、定向活检(如果VIA阳性)以及巴氏试验(如果HPV阳性、VIA阴性)。1年时的结局包括对任何检测异常者的CIN病变进行组织学或细胞学评估。
在319例接受热消融治疗的女性中,317例有基线组织学诊断结果。2例(0.6%)患有浸润性癌,36例(11.4%)患有CIN3,40例(12.6%)患有CIN2,239例(75.4%)患有CIN1/正常组织学。在127例符合随访条件的女性中,118例(92.9%)在1年时完成了所有研究程序。总体而言,98例(83.1%)没有CIN2-3或持续性低级别感染的证据,13例(11.2%)患有CIN1/意义不明确的非典型鳞状细胞,6例(5.1%)患有CIN2/高级别鳞状上皮内病变,1例(0.8%)患有持续性CIN3。未记录到与1年热消融治疗相关的不良事件。
很大一部分女性在热消融治疗1年后没有CIN2-3的证据。热消融是冷冻疗法的一种替代方法,可能有助于扩大治疗覆盖范围并预防宫颈癌导致的不必要死亡。